How to validate a self-designed peptide recovery stack before locking the schedule
Most people who build a self-designed peptide recovery stack do the schedule first: compound list, doses, injection days, cycle length, all locked before anyone with a medical license has seen it. Then something happens (a reaction, a plateau, a lab number that looks off) and the stack goes back to Reddit for a diagnosis. That's the wrong order. Validating the stack's logic before the numbers get fixed catches problems a spreadsheet can't.
The Wolverine stack runs on zero human data
BPC-157 stacked with TB-500 (thymosin β4's Frag 17-23) is common enough that the community gave it a name: the Wolverine stack, for the healing claims. There is no human trial data on the combination itself. What exists is separate, thin evidence for each compound alone. BPC-157's human data is two small Croatian Phase 1/2 trials of a rectal enema for ulcerative colitis, abstracts only, never full data released. TB-500's clinical support is a 2015 meta-analysis, mostly animal work. Neither trial tested the two together.
Two dosing numbers, neither one tested
Most users inject roughly 100-200 µg/day of BPC-157, a figure that traces back to vial size and vendor instructions, not a dose-finding study. Some clinicians argue the effective human dose is likely far higher: the strongest human data point, the ulcerative colitis enema trials, used doses up to 80 mg, orders of magnitude above the injectable norm. Nobody has run the study that would settle the gap.
TB-500 has the opposite problem: two incompatible protocols both circulate as "the" community standard. One is 750 µg daily for 20 days (15 mg total). The other is 5 mg twice a week for five weeks, then once a week for two more (roughly 60 mg total). No human RCT exists to say which is closer to right, or whether either is. Cycling shows the same split: BPC-157 users are divided between 4-6 week courses with a break and continuous use, with no data forcing a call. TB-500 mostly follows a loading-then-taper convention because that's the convention, not because a trial validated it.
Pick a schedule from any of these numbers and it's a real decision with no data behind it. That decision is worth a second set of eyes before it's locked, not after.
What qualified oversight looks like here
Neither compound is FDA-approved for this use, so the relevant standard isn't a prescription pad, it's documented informed consent from an outpatient clinician: the non-FDA-approved status stated plainly, the thin evidence acknowledged, defined endpoints, and a monitoring plan. That conversation belongs in a clinic visit. A clinician recommending BPC-157 to an inpatient on the ward, outside that documented process, risks the license; the outpatient visit with informed consent is the venue where the same recommendation is defensible.
That's also where the liability sits. Malpractice insurers don't cover non-FDA-approved peptides. If something goes wrong, exposure can reach the prescriber, the compounding pharmacy that filled it, and whoever recommended the stack in the first place, including an informal source. A Reddit thread that talked someone into a protocol carries none of that accountability. A documented clinic conversation does.
The timing that's actually shifting
This isn't a static regulatory backdrop. BPC-157 came off the FDA's do-not-compound list in April 2026 but, as of this writing, hasn't been added to the compoundable list either, so physicians have been prescribing it under its legal salt name, PDA, in the interim. Both BPC-157 and TB-500 sit on the FDA's Pharmacy Compounding Advisory Committee agenda for a July 2026 vote. Whichever way that vote lands changes what "qualified oversight" is even able to offer over the next few months, which makes locking a multi-month schedule now, ahead of that outcome, harder to justify.
Sourcing quality is part of the same validation pass, not a separate step. A stack built on a compound of unknown purity can't really be validated no matter how carefully the schedule is built. How to vet a seller covers what a real certificate of analysis needs to show before a vial gets trusted at all.
Two related reads: you're not running a protocol, you're running an experiment with no controls on why attribution breaks down without a baseline, and peptide harm reduction basics for the safety fundamentals underneath any self-run stack. More on the Ouros Lab blog.
FAQ
Is there any human trial data on the BPC-157 + TB-500 combination?
No. Each compound has separate, thin human evidence on its own (BPC-157: small Croatian enema trials for ulcerative colitis, abstracts only; TB-500: mostly an animal-model meta-analysis). The stack together has never been trialed.
What does a real BPC-157 or TB-500 certificate of analysis need to show?
Purity percentage, mass-spec confirmation, and an endotoxin reading. A COA missing mass spec or endotoxin data, or a vendor that won't produce one at all, is a red flag worth treating as disqualifying.
Why do BPC-157 dosing numbers vary so much between sources?
Because the common 100-200 µg/day range comes from vial size and vendor convention, not a dose-finding study. The one solid human data point, the Croatian ulcerative colitis enema trials, used doses up to 80 mg, far above injectable norms, so the gap between what's common and what's tested is real and unresolved.
What does "validating the logic first" actually change?
It moves the clinical review, documented informed consent covering the non-FDA-approved status and a monitoring plan, ahead of the locked schedule instead of after a reaction. A schedule built and finalized before that conversation happens turns the eventual Reddit post into damage control instead of prevention.